Scotiabank analyst Sung Ji Nam raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $12 from $10 and keeps an Outperform rating on the shares. The company ended FY24 on a “strong note,” beating expectations across the board, the analyst tells investors. The firm continues to think there is significant growth potential ahead for the company’s minimal residual disease business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Stable Performance and Strategic Guidance Support Hold Rating for Adaptive Biotechnologies
- Adaptive Biotechnologies Shines in 2024 Earnings Call
- Adaptive Biotechnologies Reports 2024 Financial Performance
- Adaptive Biotechnologies sees FY25 operating expenses $340M-$350M
- Adaptive Biotechnologies reports Q4 EPS (23c), consensus (24c)